Market Cap: $128.85B
BC
Bristol-Myers Squibb Company
BMY
NYSE (New York Stock Exchange)USD
Market Cap: $128.85B
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…
Bristol Myers Squibb Company (Ticker: BMY) is making significant strides in the field of multiple myeloma treatment with recent advancements in its clinical trials. The company announces positive resu…
BristolMyers Squibb Company (Ticker: BMY) advances its position in oncology with strategic collaborations and innovative drug development. Recently, the company enters a clinical trial collaboration w…
Bristol-Myers Squibb Company (Ticker: BMY) achieves a significant milestone in cancer treatment with the European Commission's approval of Opdivo in combination with AVD as a frontline regimen for adv…
Bristol Myers Squibb Company (Ticker: BMY) has unveiled groundbreaking findings from its Phase 3 SUCCESSOR-2 trial, showcasing the efficacy of mezigdomide in patients with relapsed or refractory multi…
Bristol Myers Squibb Company (Ticker: BMY) partners with Anthropic to enhance its operational efficiency using advanced AI technology. This collaboration marks a significant milestone as it employs Cl…
Bristol-Myers Squibb Company (Ticker: BMY) announces a groundbreaking collaboration with Hengrui Pharma aimed at developing a portfolio of 13 early-stage drug programs in oncology, hematology, and imm…
Bristol-Myers Squibb Faces Challenges in Drug Performance and Market Competition Bristol-Myers Squibb (BMY) navigates a tumultuous period marked by significant challenges affecting its core pharmaceut…
Bristol-Myers Squibb Strengthens Focus on AI Innovations in Drug Development Bristol-Myers Squibb (BMS) is increasingly emphasizing the integration of artificial intelligence (AI) in its drug discover…
BioNTech’s Commitment to Transformative Healthcare Solutions BioNTech continues to forge ahead in its mission to revolutionize healthcare with its innovative mRNA technology, particularly in the criti…
Growing Trends in Gene Therapy Investment Reflect Industry Optimism Recent financial maneuvers in the biotechnology sector indicate a significant bullish sentiment towards gene therapy companies, exem…
Bristol Myers Squibb's Breakthrough in Psoriatic Arthritis Treatment: Introducing Sotyktu Bristol Myers Squibb Company (BMY) achieves a major milestone with the U.S. approval of Sotyktu, an oral medic…
Bristol Myers Squibb's Strategic Adaptation in the Age of Artificial Intelligence In the rapidly evolving pharmaceutical landscape, companies like Bristol Myers Squibb (BMS) are increasingly recognizi…
Bristol-Myers Squibb Engages Industry Leaders in Annual Meeting to Shape Future Direction Bristol-Myers Squibb (BMY) recently convenes its annual meeting featuring influential global leaders, reflecti…
Bristol-Myers Squibb Advances Treatment for Alpha-Thalassemia with Reblozyl Study Bristol-Myers Squibb Company (BMY) announces promising topline results from a Phase 2 study evaluating Reblozyl (luspa…
Analyst Notes Highlight Strategic Uncertainty at Bristol Myers Squibb Pipeline, Patents and Pricing: The Central Debate Sixteen sell‑side analysts over the past three months deliver a wide range of vi…
White House unveils TrumpRx; Bristol Myers Squibb cuts HIV drug price Bristol Myers Squibb is among a group of drugmakers that the White House says are joining a new Trump administration initiative, T…
Pharma earnings in focus as Bristol Myers Squibb prepares for a packed results week Bristol Myers Squibb is heading into a busy corporate reporting period that industry watchers say will refocus atten…
Bristol Myers Squibb Strengthens Commitment to Innovation Through Extended Partnership with Syngene International Bristol Myers Squibb (BMS) announces a significant extension of its strategic partners…
Bristol Myers Squibb Expands Strategic Partnership with Syngene International Bristol Myers Squibb (BMS) recently announces the extension of its long-standing partnership with Syngene International, a…
Accountability in the Wake of Tragedy: Bristol Health & Rehab Center Explosion Raises Safety Concerns In a tragic incident at the Bristol Health & Rehab Center in Bristol Township, a worker named Muth…
M&A Surge Reshapes Biotech Landscape: A New Era for Pharma Companies The biopharmaceutical sector is undergoing a transformative phase driven by a surge in mergers and acquisitions (M&A). As companies…
AstraZeneca's Anifrolumab Trial Paves the Way for Autoimmune Innovations AstraZeneca Plc’s recent announcement of the successful Phase 3 TULIP-SC trial results for anifrolumab marks a pivotal developm…
Bristol-Myers Squibb: Anticipation Grows Amid Increased Investor Activity Bristol-Myers Squibb (BMS) is currently experiencing a notable surge in investor enthusiasm, particularly among those with sig…
Bristol-Myers Squibb Faces Short Interest Dynamics Amid Market Fluctuations Bristol-Myers Squibb Company, a significant player in the pharmaceutical sector, experiences a notable 4.19% rise in short i…
Bristol-Myers Squibb Faces Increased Short Interest Amid Market Sentiment Shift Bristol-Myers Squibb Company (BMY) finds itself amid a rising wave of short interest, reflecting a notable shift in mark…
Roche's Pricing Dilemma: Navigating the Global Pharmaceutical Landscape In recent statements, Thomas Schinecker, the CEO of Roche Holding AG, articulates significant concerns regarding the implication…
Transforming Drug Pricing: A New Era for Affordable Medication In a landmark initiative, President Donald Trump and nine major pharmaceutical companies, including Bristol Myers Squibb, announce agreem…
Bristol Myers Squibb's Role in Transforming Drug Pricing Landscape In a significant development for the pharmaceutical industry, Bristol Myers Squibb and other major companies engage in negotiations w…
Bristol Myers Squibb Partners with Harbour BioMed to Advance Antibody Therapeutics Bristol Myers Squibb (BMS) forges a significant partnership with Harbour BioMed, a global biopharmaceutical company s…
Bristol-Myers Squibb Faces Growing Investor Caution Amid Increased Short Interest Bristol-Myers Squibb Co., a leader in biopharmaceutical innovation, sees a notable rise in short interest among its sh…
Bristol Myers Squibb and BioNTech Aim to Transform Triple-Negative Breast Cancer Treatment Bristol Myers Squibb (BMS) and BioNTech SE are making strides in the fight against triple-negative breast can…
Bristol Myers Squibb and BioNTech Forge Ahead in Triple-Negative Breast Cancer Treatment Bristol Myers Squibb (BMS) collaborates with BioNTech SE in a Phase 2 clinical trial exploring the efficacy of…
Bristol Myers Squibb Expands Oncology Portfolio with Breyanzi Approval Bristol Myers Squibb (BMS) achieves a significant milestone as the U.S. Food and Drug Administration (FDA) grants approval for it…
Bristol Myers Squibb Expands Patient Enrollment in ADEPT-2 Clinical Study Bristol Myers Squibb Company (NYSE:BMY) makes a significant move by announcing an expansion of patient enrollment in the ADEPT…
Bristol Myers Squibb Expands ADEPT-2 Study Enrollment to Bolster Clinical Insights Bristol Myers Squibb Company (NYSE:BMY) enhances its commitment to advancing medical research by announcing an expans…
Bayer's Breakthrough in Atrial Fibrillation Treatment: The OCEANIC-STROKE Study Bayer AG’s recent announcement of the topline results from its Phase 3 OCEANIC-STROKE study marks a significant advancem…
Texas Attorney General's Lawsuit Highlights Accountability in Pharmaceutical Industry Texas Attorney General Ken Paxton has escalated his legal campaign against major pharmaceutical companies by filin…
Bristol-Myers Squibb Faces Legal Challenges Over Plavix Efficacy Claims Bristol-Myers Squibb Company finds itself embroiled in a significant legal battle as a lawsuit filed by McKool Smith, in collabo…
Bristol Myers Squibb Faces Industry Challenges Amid Market Shifts In the ever-evolving pharmaceutical landscape, Bristol Myers Squibb (BMS) navigates a myriad of challenges as it strives to maintain i…
Bristol-Myers Squibb: Navigating the Future of Cancer Treatments Amidst Market Volatility Bristol-Myers Squibb Company (BMS) continues to solidify its position in the pharmaceutical industry through a…
### Advancements in Gene Therapy: The Rise of uniQure uniQure, a biotechnology firm specializing in gene therapies, is currently experiencing a surge of interest from wealthy investors, often referred…
Bristol Myers Squibb's Strategic Focus on Cobenfy Amid Mixed Q3 Performance Bristol Myers Squibb (BMS) reports a mixed performance for its third quarter ending September 30, 2023, with total revenue r…
Bristol-Myers Squibb Prepares for Key Earnings Report Amid Product Performance Focus As Bristol-Myers Squibb (BMY) gears up for its quarterly earnings report set to be released on October 30, 2025, th…
Bristol Myers Squibb Faces Competitive Pressure in Cardiac Treatment Market Bristol Myers Squibb (BMS) is currently navigating a challenging landscape in the pharmaceutical industry, particularly with…
Bristol Myers Squibb Faces Competitive Pressure Amid Industry Consolidation Bristol Myers Squibb (BMS) stands at a crucial juncture in a rapidly evolving biotechnology landscape, particularly followin…
Bristol Myers Squibb Poised for Key Earnings Report Amid Market Optimism As Bristol Myers Squibb prepares to report its earnings next week, the pharmaceutical giant finds itself in a favorable market…
Breakthrough in Lung Cancer Treatment: Iza-bren Shows Promise in Phase I Trials Bristol Myers Squibb collaborates with SystImmune Inc. to advance the development of iza-bren (BL-B01D1), a bispecific a…
Bristol Myers Squibb Celebrates Global Patient Week with Community Initiatives In a significant display of its commitment to patient-centric care, Bristol Myers Squibb (BMS) marks the 11th anniversary…
Bristol Myers Squibb's Strategic Collaboration in Breast Cancer Treatment Development Bristol Myers Squibb (BMS) continues to strengthen its position in the oncology market through a significant colla…